Navigation Links
VentriPoint Diagnostics Files Management Discussion and Analysis, Unaudited Financial Results for 2Q 2008
Date:8/29/2008

New Date for Anticipated VentriPoint Diagnostic System Launch, Alpha

Testing Commencement Highlight Management Discussion and Analysis

SEATTLE, Aug. 29 /PRNewswire-FirstCall/ -- VentriPoint Diagnostics (TSX: VPT) today announced that it has filed its management discussion and analysis (MD&A), as well as its unaudited financial results for the three months ended June 30, 2008, with the Canadian Securities Administrators through the SEDAR filing system.

Development Highlights

In its MD&A, VentriPoint describes that because of the recent accomplishments by its development team, the commercial product release of the VentriPoint Diagnostic System is now anticipated to commence in January 2009 instead of March 2009 as previously expected. Other recent milestones include the approval and commencement of alpha testing, transition of the Knowledge Reconstruction Database to its commercial and secure off-site facility, and initiation of the design and production of the product training guide and user's manual.

"Our team has been working diligently to bring the VentriPoint Diagnostic System to market to offer accurate heart measurements in a rapid and inexpensive manner that is not currently available," said Joseph Ashley, CEO of VentriPoint Diagnostics. "We have commenced in-house alpha testing, and we look forward to shipping our units for beta testing in October."

Financial Highlights

In its unaudited financial results, VentriPoint reported a consolidated net loss of $1,062,182 for the three months ended June 30, 2008, or $0.03 per share, compared to a net loss of $193,038, or $0.02 per share for the three months ended June 30, 2007. The increase in net loss is attributed to planned expenditures to accelerate the development of the VentriPoint Diagnostic System.

For the three months ended June 30, 2008, research and development expenses totaled $651,276, compared to $143,563 for the three months ended June 30, 2007. The largest research and development expense for the three months ended June 30, 2008 was payroll costs to build a highly qualified research and development team.

VentriPoint reported a foreign exchange loss of $99,568 as the result of a change in the currency exchange rate used to translate Canadian monetary items into the US dollar on the date of translation of June 30, 2008.

About VentriPoint Diagnostics

VentriPoint creates diagnostic tools to monitor patients with heart disease -- the number one cause of death in developed countries. By using images produced from existing medical imaging systems, the VentriPoint Diagnostic System generates accurate heart measurements in a rapid and inexpensive manner not currently available. This breakthrough diagnostic tool is based upon patented technology received by VentriPoint through its exclusive technology license with the University of Washington. The VentriPoint Diagnostic System, together with its associated online service, is being developed for a variety of heart related disease states, including congenital heart disease.

For further information, please contact:

Edward Garth, Chief Financial Officer

VentriPoint Diagnostics Ltd.

Telephone: (206) 283-0221, ext. 402

Facsimile: (206) 283-2309

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

VentriPoint Media Contact:

Russo Partners LLC

Ian Stone

(619) 814-3510

ian.stone@russopartnersllc.com


'/>"/>
SOURCE VentriPoint Diagnostics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VentriPoint, University of Washington Sign Research and Technology Development Agreement
2. Strategic Diagnostics to Present at Two Upcoming Investor Conferences
3. Strategic Diagnostics Updates Roth Conference Presentation Time
4. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
5. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
6. Indivumed Supports Roche Diagnostics With Immunohistochemistry Services and Clinical Specimens for Biomarker Discovery and Drug Development
7. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
8. BoVir(R) Named Best New Veterinary Diagnostics Product in International Animal Pharm Awards
9. Enigma Diagnostics Announces a European Commission Award of EUR3 Million to Fund the Development of a Point of Care Platform for the Rapid Diagnosis of Influenza Infections
10. MedAssets Supply Chain Systems Selects Siemens Medical Solutions Diagnostics for Chemistry, Automation and Immunoassay Solutions
11. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ON (PRWEB) , ... May 05, 2016 , ... ... following the previously announced identification of its first three targets, it has identified ... misfolded Amyloid beta (Aß), implicated in the development and progression of Alzheimer’s disease ...
(Date:5/4/2016)... CA (PRWEB) , ... May 04, 2016 , ... ... Well, look no further than LaJollaCooks4u, San Diego’s premiere hands-on cooking experience. Offering ... need to give mom an experience she won’t forget. , Guests that visit ...
(Date:5/4/2016)... , May 4, 2016  Bayer today ... oncology compound Stivarga ® (regorafenib) tablets for ... (HCC) has met its primary endpoint of a ... called RESORCE, evaluated the efficacy and safety of ... progressed after treatment with sorafenib. The safety and ...
(Date:5/4/2016)... New York , May 4, 2016 ... by Transparency Market Research "Metabolomics Market - Global Industry ... 2024", the metabolomics market is anticipated to expand at ... reach USD 2,494.8 million by 2024. Metabolomics ... as metabolites, within cells, biofluids, tissues or organisms. Together, ...
Breaking Biology Technology:
(Date:3/22/2016)... 22, 2016 According ... Market for Consumer Industry by Type (Image, Motion, ... (Communication & IT, Entertainment, Home Appliances, & ... to 2022", published by MarketsandMarkets, the market ... reach USD 26.76 Billion by 2022, at ...
(Date:3/17/2016)... -- ABI Research, the leader in transformative technology ... will reach more than $30 billion by 2021, ... electronics, particularly smartphones, continue to boost the biometrics ... two billion shipments by 2021 at a 40% ... Analyst at ABI Research. "Surveillance is also gearing ...
(Date:3/14/2016)... Allemagne, March 14, 2016 ... - --> - Renvoi : image disponible ... --> --> DERMALOG, ... fournit de nouveaux lecteurs d,empreintes digitales pour l,enregistrement ... DERMALOG sera utilisé pour produire des cartes d,identité ...
Breaking Biology News(10 mins):